Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause
Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of 4 doses of
desvenlafaxine-233 sustained release (DVS-233 SR) as compared to placebo for the treatment of
moderate to severe vasomotor symptoms associated with menopause, as well as its influence on
sleep parameters and other health outcomes indicators.